The pandemic reduced visits to specialists last year, which in turn reduced the volume of prescriptions, according to a presentation at the Academy of Managed Care Pharmacy 2021 meeting.
In 2020, COVID-19 had an impact on diagnostic visits to specialists that in turn affected the volume of pharmaceutical prescriptions, as well as the use of acute medications due to the lack of a cold and flu season.
And while Douglas M. Long, BS, MBA, vice president, Industry Relations, IQVIA, said COVID-19 will continue to have an impact on the marketplace going forward, he told the virtual audience at the Academy of Managed Care Pharmacy 2021 meeting that the effect of the pandemic will lessen, although there are a number of what he called “wildcards.”
During his annual talk on pharmaceutical marketplace trends, he said there were a billion fewer diagnosis visits that took place in 2020, and a 21% reduction in expected diagnosis visits, he said. The top 5 specialties affected were oncology, gastroenterology, dermatology, ophthalmology, and anesthesiology, as people skipped screening tests like mammograms or getting eye care.
Some specialties had what he called “moments of growth,” such as dermatology seeing a spike in visits in June and July and psychiatry jumping in August and September.
That diagnosis gap is expected to continue in 2021, although it will be a lot less—about a 12% drop in expected visits, and 288 million fewer visits than expected. Whether that creates a new baseline will depend on the continued deployment of COVID-19 vaccines as well as the country reaching herd immunity. IQVIA's chief medical officer is optimistic and thinks it is possible for that to happen by the end of the third quarter, Long said.
But those fewer visits translate into fewer prescriptions, he said—about a 3.8% drop from January 2020 to June 2021, or about 111 million, based on an average 30 days’ supply. Oncology saw 30% fewer prescriptions and drugs for pediatric indications, 45%.
The IQVIA data also looked at telehealth, which does not generate as many prescriptions, Long said. Dermatology did not compensate for the decline in in-person visits with telehealth, but other specialties, notably rheumatology and gastroenterology, did.
Pharmaceutical trends
A few of the pharmaceutical trends Long highlighted include:
Outlook for rest of 2021
Looking ahead, cost and price will be an issue for just about all stakeholders, Long said. Payers are coping with rising oncology drug costs and managing the costs of other specialty drugs. Consumers continue to face rising out-of-pocket costs and coinsurance amounts.
There's growing net price pressure in immunology and other specialty markets, he said.
Branded drug makers are looking to become more specialized and focus more on orphan drugs while also facing a backlash against price increases.
And generic price deflation will affect both wholesalers as well as generic manufacturers, both of whom are turning to purchasing alliances.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More